GSK to cap out-of-pocket inhaler costs in US
March 20 (Reuters) - British pharmaceutical giant GSK (GSK.L), opens new tab said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for eligible patients in the United States, following similar moves by two of its rivals.
Takeda's treatment becomes first oral therapy for esophageal condition in US
Feb 12 (Reuters) - Takeda Pharmaceutical's (4502.T) therapy for an allergic inflammation of the esophagus has received approval from the U.S. FDA, the Japanese drugmaker said on Monday, capping a years-long regulatory process.
Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak associated with Artificial Tears
Carbapenemase-producing, carbapenem-resistant Pseudomonas aeruginosa (CP-CRPA) are extensively drug resistant bacteria. We investigated the source of a multistate CP-CRPA outbreak.
Health Headlines: New hope for children with peanut allergies
ATLANTA, Ga. (Ivanhoe Newswire) – More than five and a half million kids have a food allergy, that’s about one in 13 kids, or one or two kids in every single classroom. Even though more than 170 foods have been reported to cause allergies, eggs, milk, and peanuts are the most common. Recently, the FDA approved an oral treatment for older children with peanut allergies, but there was no treatment for children under the age of four, until now.
Why our allergies are getting worse - and what to do about it
If it seems like your seasonal allergies are getting worse over time, you're probably not wrong. Estimates are that 30 to 40% of the world's population now have some form of allergy, and medical anthropologist Theresa MacPhail says allergic reactions — including everything from hay fever to eczema and asthma — are growing in the U.S. and around the world.